Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Journal of Immunology (Baltimore, Md. : 1950)|March 1, 1992
Protective effects of soluble CR1 in complement- and neutrophil-mediated tissue injuryM S Mulligan, C G Yeh, A R Rudolph, et al.Journal of Biological Response Modifiers|October 1, 1989
A phase I trial of subcutaneously administered recombination tumor necrosis factor to patients with advanced malignancyK W Zamkoff, N B Newman, A R Rudolph, et al.Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|February 1, 1992
A phase I trial of recombinant human macrophage colony-stimulating factor by rapid intravenous infusion in patients with refractory malignancyK W Zamkoff, J Hudson, E S Groves, et al.Journal of Biological Response Modifiers|August 1, 1989
Exacerbation of epidemic Kaposi's sarcoma with a combination of interleukin-2 and beta-interferon: results of a phase 2 studyR L Krigel, K A Padavic-Shaller, A R Rudolph, et al.Journal of Neurosurgery|February 1, 1987
Mixed germ-cell tumor of the pineal region. Case reportS L Graziano, F P Paolozzi, A R Rudolph, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1990
Renal cell carcinoma: treatment with recombinant interleukin-2 plus beta-interferonR L Krigel, K A Padavic-Shaller, A R Rudolph, et al.Journal of the American Society of Nephrology : JASN|May 1, 1995
The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritisW G Couser, R J Johnson, B A Young, et al.Cancer|June 1, 1993
A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanomaL E Flaherty, W Robinson, B G Redman, et al.Cancer Research|July 1, 1988
A phase I study of recombinant interleukin 2 plus recombinant beta-interferonR L Krigel, K A Padavic-Shaller, A R Rudolph, et al.Journal of Immunology (Baltimore, Md. : 1950)|May 15, 1992
Lung injury after deposition of IgA immune complexes. Requirements for CD18 and L-arginineM S Mulligan, J S Warren, C W Smith, et al.Pageof 2